

Recombinant Human PLGF/PGF protein (His Tag)

Catalog Number: PDEH100881



Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Species	Human
Source	E.coli-derived Human PLGF protein Leu19-Arg149, with an C-terminal His
Mol_Mass	14.3 kDa
Accession	P49763-2
Bio-activity	Not validated for activity

Properties

Purity	> 95% as determined by reducing SDS-PAGE.
Endotoxin	< 10 EU/mg of the protein as determined by the LAL method
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with 5% Trehalose and 5% Mannitol.
Reconstitution	It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

For Research Use Only

A Reliable Research Partner in Life Science and Medicine
Tel:400-999-2100

Email:techsupport@elabscience.cn

Web:www.elabscience.cn

Rev. V1.3

Recombinant Human PLGF/PGF protein (His Tag)

Catalog Number: PDEH100881



Placenta growth factor (PGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines . Alternative splicing results in at least three human mature PGF forms containing 131 (PGF-1), 152 (PGF-2), and 203 (PGF-3) amino acids (aa) respectively . Only PGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus . Human PGF-1 shares 56%, 55%, 74% and 95% aa identity with the comparable isoform of mouse, rat, canine, and equine PGF, respectively. PGF is mainly found as variably glycosylated, secreted, 55-60 kDa disulfide linked homodimers . Mammalian cells expressing PGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes, and some endothelial cells . Circulating PGF increases during pregnancy, reaching a peak in mid-gestation, this increase is attenuated in preeclampsia . However, deletion of PGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PGF show impaired angiogenesis in response to ischemia . PGF binds and signals through VEGF R1/Flt-1 but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PGF and VEGF therefore compete for binding to VEGF R1, allowing high PGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis . However, PGF (especially PGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2 . PGF-2, but not PLGF-1, shows heparin-dependent binding of Neuropilin (Npn)-1 and Npn-2 . PGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound, bone fracture, and cardiac repair, but also contribute to inflammation in active sickle cell disease and atherosclerosis . PGF can also inhibit TIMP3 expression in the spleen, leading to immune triggering of hypertension .

For Research Use Only

A Reliable Research Partner in Life Science and Medicine
Tel:400-999-2100

Email:techsupport@elabscience.cn

Web:www.elabscience.cn

Rev. V1.3